On December 15, 2023, Jazz Pharmaceuticals plc announced that Kim Sablich, Executive Vice President and General Manager, US, will be departing the company, and that effective as of December 31, 2023, Ms. Sablich will no longer serve in that role or as an executive officer of the company.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
103.5 USD | -1.48% |
|
-3.39% | -15.83% |
07-01 | Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell 1000 Growth Index | CI |
07-01 | Jazz Pharmaceuticals plc(NasdaqGS:JAZZ) dropped from Russell Midcap Growth Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.83% | 6.53B | |
+54.07% | 809B | |
+39.48% | 621B | |
-7.05% | 351B | |
+15.44% | 319B | |
+5.72% | 289B | |
+14.77% | 238B | |
-0.53% | 221B | |
+14.53% | 218B | |
+7.42% | 166B |
- Stock Market
- Equities
- JAZZ Stock
- News Jazz Pharmaceuticals plc
- Kim Sablich to Departure as Executive Vice President and General Manager, US of Jazz Pharmaceuticals plc on December 31, 2023